Windtree Therapeutics expects data useful for an end of Phase 2 meeting.
1 report, 0 independent
Updated Jun 30
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Windtree Therapeutics expects data useful for an end of Phase 2 meeting.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Windtree Therapeutics (United States)
company in Philadelphia, United States
Nothing else this week.
Related events
- The FDA requested additional clinical data from Unicycive Therapeutics.
- Data was presented in Athens supporting a future U.S. NDA submission to the FDA.
- GSK is submitting data to the FDA regarding potential expansion of its drug indications.
- The FDA is reviewing drug data and company resubmissions, while also overseeing the functions of the U.S. Department of Health and Human Services.
- A study protocol involving a company based in Mont-Saint-Guibert was approved by the U.S. FDA.
Coverage
Newest first; wire copies grouped- Unknown outlet